{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:56:21Z","timestamp":1787702181699,"version":"build-2784847793"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001697","name":"Keio University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001697","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jconrel.2025.113681","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T03:57:53Z","timestamp":1743739073000},"page":"113681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["TGFBI R124H mutant allele silencing in granular corneal dystrophy type 2 using topical siRNA delivery"],"prefix":"10.1016","volume":"382","author":[{"given":"Andrew","family":"McLain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Kowalczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Baran-Rachwalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia Maria","family":"Sutera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise J.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia Sukusu","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Enghild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cobice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Bonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Barbaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Andrew","family":"Nesbit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jconrel.2025.113681_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113681_bb0010","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s13346-015-0275-6","article-title":"In vitro and ex vivo corneal penetration and absorption models","volume":"6","author":"Agarwal","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113681_bb0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/nat.2020.0919","article-title":"Impact of serum proteins on the uptake and RNAi activity of GalNAc-conjugated siRNAs","volume":"31","author":"Agarwal","year":"2021","journal-title":"Nucleic Acid Ther."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113681_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023443","article-title":"Designing of highly effective complementary and mismatch siRNAs for silencing a gene","volume":"6","author":"Ahmed","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113681_bb0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/ph17020243","article-title":"2023 FDA TIDES (peptides and oligonucleotides) harvest","volume":"17","author":"Al Shaer","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"24","key":"10.1016\/j.jconrel.2025.113681_bb0030","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic Givosiran for acute intermittent Porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.113681_bb0035","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jconrel.2020.07.004","article-title":"Topical siRNA delivery to the cornea and anterior eye by hybrid silicon-lipid nanoparticles","volume":"326","author":"Baran-Rachwalska","year":"2020","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113681_bb0040","doi-asserted-by":"crossref","first-page":"11754","DOI":"10.1038\/s41598-020-68254-1","article-title":"Rapid assessment of ocular drug delivery in a novel ex vivo corneal model","volume":"10","author":"Begum","year":"2020","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113681_bb0045","first-page":"3954","article-title":"Long-term safety studies of tivanisiran for the treatment of dry eye disease (DED)","volume":"64","author":"Bleau","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113681_bb0050","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.1038\/s41467-021-25185-3","article-title":"PERM1 interacts with the MICOS-MIB complex to connect the mitochondria and sarcolemma via ankyrin B","volume":"12","author":"Bock","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113681_bb0055","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.molcel.2015.04.028","article-title":"Choosing the right tool for the job: RNAi, TALEN, or CRISPR","volume":"58","author":"Boettcher","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jconrel.2025.113681_bb0060","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.omtn.2020.07.032","article-title":"USP10 targeted self-deliverable siRNA to prevent scarring in the cornea","volume":"21","author":"Boumil","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113681_bb0065","first-page":"207","article-title":"The mighty mouse: the impact of rodents on advances in biomedical research","volume":"110","author":"Bryda","year":"2013","journal-title":"Mo. Med."},{"key":"10.1016\/j.jconrel.2025.113681_bb0070","first-page":"70","article-title":"Reduced penetrance in familial Avellino corneal dystrophy associated with TGFBI mutations","volume":"15","author":"Cao","year":"2009","journal-title":"Mol. Vis."},{"key":"10.1016\/j.jconrel.2025.113681_bb0075","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s13287-018-1036-5","article-title":"Corneal cell therapy: with iPSCs, it is no more a far-sight","volume":"9","author":"Chakrabarty","year":"2018","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"10.1016\/j.jconrel.2025.113681_bb0080","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41433-019-0346-x","article-title":"Evaluation of TGFBI corneal dystrophy and molecular diagnostic testing","volume":"33","author":"Chao-Shern","year":"2019","journal-title":"Eye"},{"issue":"35","key":"10.1016\/j.jconrel.2025.113681_bb0085","doi-asserted-by":"crossref","first-page":"25207","DOI":"10.1074\/jbc.M113.489674","article-title":"Peroxisome proliferator-activated receptor \u03b3 coactivator 1 (PGC-1)- and estrogen-related receptor (ERR)-induced regulator in muscle 1 (Perm1) is a tissue-specific regulator of oxidative capacity in skeletal muscle cells","volume":"288","author":"Cho","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2025.113681_bb0090","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.molmet.2019.02.009","article-title":"Perm1 regulates CaMKII activation and shapes skeletal muscle responses to endurance exercise training","volume":"23","author":"Cho","year":"2019","journal-title":"Mol. Metab."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113681_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100825","article-title":"Perm1 promotes cardiomyocyte mitochondrial biogenesis and protects against hypoxia\/reoxygenation-induced damage in mice","volume":"297","author":"Cho","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113681_bb0100","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.ymthe.2020.05.002","article-title":"Mutation-independent allele-specific editing by CRISPR-Cas9, a novel approach to treat autosomal dominant disease","volume":"28","author":"Christie","year":"2020","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113681_bb0105","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1261\/rna.1161908","article-title":"Potent RNAi by short RNA triggers","volume":"14","author":"Chu","year":"2008","journal-title":"RNA"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113681_bb0110","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/gt.2015.82","article-title":"CRISPR\/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting","volume":"23","author":"Courtney","year":"2016","journal-title":"Gene Ther."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113681_bb0115","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1167\/iovs.13-12957","article-title":"siRNA silencing of the mutant keratin 12 allele in corneal limbal epithelial cells grown from patients with Meesmann's epithelial corneal dystrophy","volume":"55","author":"Courtney","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113681_bb0120","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1167\/iovs.13-13279","article-title":"Development of allele-specific gene-silencing siRNAs for TGFBI Arg124Cys in lattice corneal dystrophy type I","volume":"55","author":"Courtney","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113681_bb0125","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/psp4.12381","article-title":"Best practices to maximize the use and reuse of quantitative and systems pharmacology models: recommendations from the United Kingdom quantitative and systems pharmacology network","volume":"8","author":"Cucurull-Sanchez","year":"2019","journal-title":"Pharmacometr. Syst. Pharmacol."},{"issue":"9","key":"10.1016\/j.jconrel.2025.113681_bb0130","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.ophtha.2014.03.038","article-title":"Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study","volume":"121","author":"Cursiefen","year":"2014","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.jconrel.2025.113681_bb0135","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1080\/07391102.2012.736758","article-title":"An siRNA designing tool with a unique functional off-target filtering approach","volume":"31","author":"Das","year":"2013","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113681_bb0140","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00415-012-6521-7","article-title":"C19orf12 mutations in neurodegeneration with brain iron accumulation mimicking juvenile amyotrophic lateral sclerosis","volume":"259","author":"Deschauer","year":"2012","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113681_bb0145","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.biomaterials.2006.11.028","article-title":"Ocular drug delivery by liposome\u2013chitosan nanoparticle complexes (LCS-NP)","volume":"28","author":"Diebold","year":"2007","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.jconrel.2025.113681_bb0150","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0161-6420(00)00657-6","article-title":"Alteration of the ocular surface with recurrence of granular\/Avellino corneal dystrophy after phototherapeutic keratectomy: report of five cases and literature review","volume":"108","author":"Dogru","year":"2001","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113681_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-28545-0","article-title":"A mouse model of Schnyder corneal dystrophy with the N100S point mutation","volume":"8","author":"Dong","year":"2018","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113681_bb0160","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3390\/cells8050403","article-title":"Current challenges of iPSC-based disease modeling and therapeutic implications","volume":"8","author":"Doss","year":"2019","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.jconrel.2025.113681_bb0165","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1021\/pr300358k","article-title":"Human cornea proteome: identification and quantitation of the proteins of the three main layers including epithelium, stroma, and endothelium","volume":"11","author":"Dyrlund","year":"2012","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.jconrel.2025.113681_bb0170","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/bs.pmbts.2015.04.001","article-title":"Overview of the cornea: structure, function, and development","volume":"134","author":"Eghrari","year":"2015","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.jconrel.2025.113681_bb0175","author":"European Medicines Agency"},{"key":"10.1016\/j.jconrel.2025.113681_bb0180","series-title":"Givlaari (Givosiran) an Overview of Givlaari and why it Is Authorised in the EU","author":"European Medicines Agency","year":"2020"},{"key":"10.1016\/j.jconrel.2025.113681_bb0185","author":"European Medicines Agency"},{"key":"10.1016\/j.jconrel.2025.113681_bb0190","author":"European Medicines Agency"},{"key":"10.1016\/j.jconrel.2025.113681_bb0195","author":"European Medicines Agency"},{"issue":"13","key":"10.1016\/j.jconrel.2025.113681_bb0200","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1167\/iovs.16-19818","article-title":"Genotype-phenotype correlation for TGFBI corneal dystrophies identifies p.(G623D) as a novel cause of epithelial basement membrane dystrophy","volume":"57","author":"Evans","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113681_bb0205","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12974-021-02162-7","article-title":"Capsazepine decreases corneal pain syndrome in severe dry eye disease","volume":"18","author":"Fakih","year":"2021","journal-title":"J. Neuroinflammation"},{"issue":"6669","key":"10.1016\/j.jconrel.2025.113681_bb0210","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.jconrel.2025.113681_bb0215","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/archopht.1994.01090200086027","article-title":"The relationship between granular, lattice type 1, and Avellino corneal dystrophies. A histopathologic study","volume":"112","author":"Folberg","year":"1994","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.jconrel.2025.113681_bb0220","author":"Food and Drug Administration"},{"key":"10.1016\/j.jconrel.2025.113681_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.701031","article-title":"An overview of methods and tools for transfection of eukaryotic cells in vitro","volume":"9","author":"Fus-Kujawa","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"13","key":"10.1016\/j.jconrel.2025.113681_bb0230","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary Hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113681_bb0235","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/brain\/awz139","article-title":"Allele-specific silencing as treatment for gene duplication disorders: proof-of-principle in autosomal dominant leukodystrophy","volume":"142","author":"Giorgio","year":"2019","journal-title":"Brain J. Neurol."},{"issue":"20","key":"10.1016\/j.jconrel.2025.113681_bb0240","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/bioinformatics\/btn442","article-title":"siDRM: an effective and generally applicable online siRNA design tool","volume":"24","author":"Gong","year":"2008","journal-title":"Bioinformatics"},{"issue":"24","key":"10.1016\/j.jconrel.2025.113681_bb0245","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMe2010986","article-title":"Givosiran - running RNA interference to fight Porphyria attacks","volume":"382","author":"Gonzalez-Aseguinolaza","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.113681_bb0250","first-page":"1755","article-title":"Extremely varied phenotypes in granular corneal dystrophy type 2 heterozygotes","volume":"18","author":"Han","year":"2012","journal-title":"Mol. Vis."},{"key":"10.1016\/j.jconrel.2025.113681_bb0255","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.preteyeres.2015.11.002","article-title":"Pathogenesis and treatments of TGFBI corneal dystrophies","volume":"50","author":"Han","year":"2016","journal-title":"Prog. Retin. Eye Res."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113681_bb0260","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ajhg.2011.09.007","article-title":"Absence of an orphan mitochondrial protein, C19orf12, causes a distinct clinical subtype of neurodegeneration with brain Iron accumulation","volume":"89","author":"Hartig","year":"2011","journal-title":"Am. J. Hum. Genet."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113681_bb0265","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0161-6420(92)31766-X","article-title":"Avellino corneal dystrophy. Clinical manifestations and natural history","volume":"99","author":"Holland","year":"1992","journal-title":"Ophthalmology"},{"issue":"15","key":"10.1016\/j.jconrel.2025.113681_bb0270","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","article-title":"Patisiran: first global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113681_bb0275","article-title":"PERM1 regulates genes involved in fatty acid metabolism in the heart by interacting with PPAR\u03b1 and PGC-1\u03b1","volume":"12","author":"Huang","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113681_bb0280","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2144\/000113132","article-title":"Transcriptional effects of transfection: the potential for misinterpretation of gene expression data generated from transiently transfected cells","volume":"47","author":"Jacobsen","year":"2009","journal-title":"BioTechniques"},{"issue":"5","key":"10.1016\/j.jconrel.2025.113681_bb0285","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1167\/iovs.62.5.6","article-title":"IMI prevention of myopia and its progression","volume":"62","author":"Jonas","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113681_bb0290","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ophtha.2003.06.026","article-title":"Avellino corneal dystrophy after LASIK","volume":"111","author":"Jun","year":"2004","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.jconrel.2025.113681_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232111","article-title":"Ex-vivo cultured human corneoscleral segment model to study the effects of glaucoma factors on trabecular meshwork","volume":"15","author":"Kasetti","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113681_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-58876-w","article-title":"Generation of mouse model of TGFBI-R124C corneal dystrophy using CRISPR\/Cas9-mediated homology-directed repair","volume":"10","author":"Kitamoto","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113681_bb0305","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1021\/acsomega.1c06455","article-title":"siRNA seed region is divided into two functionally different domains in RNA interference in response to 2'-OMe modifications","volume":"7","author":"Kobayashi","year":"2022","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113681_bb0310","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2025.113681_bb0315","doi-asserted-by":"crossref","first-page":"11465","DOI":"10.1074\/jbc.275.15.11465","article-title":"Amyloid and non-amyloid forms of 5q31-linked corneal dystrophy resulting from Kerato-epithelin mutations at Arg-124 are associated with abnormal turnover of the protein","volume":"275","author":"Korvatska","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2025.113681_bb0320","article-title":"Single-cell kinetics of siRNA-mediated mRNA degradation","volume":"21","author":"Krzyszto\u0144","year":"2019","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113681_bb0325","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4103\/2231-4040.85540","article-title":"Reduction in drop size of ophthalmic topical drop preparations and the impact of treatment","volume":"2","author":"Kumar","year":"2011","journal-title":"J. Adv. Pharm. Technol. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113681_bb0330","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2025.113681_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2019.107715","article-title":"Clinical and genetic update of corneal dystrophies","volume":"186","author":"Lisch","year":"2019","journal-title":"Exp. Eye Res."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113681_bb0340","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13063-017-1861-3","volume":"18","author":"Lorenz","year":"2017","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.jconrel.2025.113681_bb0345","doi-asserted-by":"crossref","DOI":"10.1002\/prca.201900072","article-title":"Protein analysis of the TGFBIR124H mouse model gives insight into phenotype development of granular corneal dystrophy","volume":"14","author":"Lukassen","year":"2020","journal-title":"Proteomics Clin. Appl."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113681_bb0350","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3349\/ymj.2017.58.2.423","article-title":"Role of TGFBIp in wound healing and mucin expression in corneal epithelial cells","volume":"58","author":"Maeng","year":"2017","journal-title":"Yonsei Med. J."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113681_bb0355","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4274\/tjo.galenos.2019.55770","article-title":"Investigation of TGFBI (transforming growth factor beta-induced) gene mutations in families with granular corneal dystrophy type 1 in the Konya region","volume":"50","author":"Malkondu","year":"2020","journal-title":"Turk. J. Ophthalmol."},{"issue":"Suppl. 2","key":"10.1016\/j.jconrel.2025.113681_bb0360","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10072-020-04889-2","article-title":"Hereditary transthyretin amyloidosis overview","volume":"43","author":"Manganelli","year":"2022","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.jconrel.2025.113681_bb0365","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.omtn.2023.08.020","article-title":"Novel hybrid silicon-lipid nanoparticles deliver a siRNA to cure autosomal dominant osteopetrosis in mice. Implications for gene therapy in humans","volume":"33","author":"Maurizi","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"6","key":"10.1016\/j.jconrel.2025.113681_bb0370","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1124\/dmd.121.000428","article-title":"The nonclinical disposition and pharmacokinetic\/Pharmacodynamic properties of N-Acetylgalactosamine-conjugated small interfering RNA are highly predictable and build confidence in translation to human","volume":"50","author":"McDougall","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jconrel.2025.113681_bb0375","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.parkreldis.2017.12.025","article-title":"A de novo C19orf12 heterozygous mutation in a patient with MPAN","volume":"48","author":"Monfrini","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113681_bb0380","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1021\/acs.molpharmaceut.2c00510","article-title":"Efficacy of asymmetric siRNA targeting androgen receptors for the treatment of androgenetic alopecia","volume":"20","author":"Moon","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.113681_bb0385","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.preteyeres.2018.01.004","article-title":"Personalised genome editing \u2013 the future for corneal dystrophies","volume":"65","author":"Moore","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113681_bb0390","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/13543784.2018.1457647","article-title":"Tivanisiran, a novel siRNA for the treatment of dry eye disease","volume":"27","author":"Moreno-Monta\u00f1\u00e9s","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"7","key":"10.1016\/j.jconrel.2025.113681_bb0395","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3390\/cells11071131","article-title":"The non-linear path from gene dysfunction to genetic disease: lessons from the MICPCH mouse model","volume":"11","author":"Mukherjee","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2025.113681_bb0400","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s42826-022-00128-1","article-title":"Role of animal models in biomedical research: a review","volume":"38","author":"Mukherjee","year":"2022","journal-title":"Lab. Anim. Res."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113681_bb0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025642","article-title":"MysiRNA-designer: a workflow for efficient siRNA design","volume":"6","author":"Mysara","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2025.113681_bb0410","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fgene.2012.00102","article-title":"siRNA design software for a target gene-specific RNA interference","volume":"3","author":"Naito","year":"2012","journal-title":"Front. Genet."},{"key":"10.1016\/j.jconrel.2025.113681_bb0415","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/1471-2105-10-392","article-title":"siDirect 2.0: updated software for designing functional siRNA with reduced seed-dependent off-target effect","volume":"10","author":"Naito","year":"2009","journal-title":"BMC Bioinf."},{"issue":"15","key":"10.1016\/j.jconrel.2025.113681_bb0420","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s40265-023-01943-z","article-title":"Vutrisiran: a review in polyneuropathy of hereditary transthyretin-mediated amyloidosis","volume":"83","author":"Nie","year":"2023","journal-title":"Drugs"},{"issue":"2\u20133","key":"10.1016\/j.jconrel.2025.113681_bb0425","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.brainresbull.2009.08.009","article-title":"Characterisation and functional features of a spontaneously immortalised human corneal epithelial cell line with progenitor-like characteristics","volume":"81","author":"Notara","year":"2010","journal-title":"Brain Res. Bull."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113681_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2022.100150","article-title":"Successful proof-of-concept for topical delivery of novel peptide ALM201 with potential usefulness for treating Neovascular eye disorders","volume":"2","author":"Obasanmi","year":"2022","journal-title":"Ophthalmol. Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113681_bb0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002248","article-title":"Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi","volume":"3","author":"Ohnishi","year":"2008","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jconrel.2025.113681_bb0440","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234913","article-title":"Perm1 regulates cardiac energetics as a downstream target of the histone methyltransferase Smyd1","volume":"15","author":"Oka","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2025.113681_bb0445","first-page":"283","article-title":"Prevalence of granular corneal dystrophy type 2-related TGFBI p.R124H variant in a south Korean population","volume":"27","author":"Park","year":"2021","journal-title":"Mol. Vis."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113681_bb0450","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/febs.14321","article-title":"Proteomic profiling of TGFBI-null mouse corneas reveals only minor changes in matrix composition supportive of TGFBI knockdown as therapy against TGFBI-linked corneal dystrophies","volume":"285","author":"Poulsen","year":"2018","journal-title":"FEBS J."},{"issue":"16","key":"10.1016\/j.jconrel.2025.113681_bb0455","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.jconrel.2025.113681_bb0460","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of Inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113681_bb0465","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nbt936","article-title":"Rational siRNA design for RNA interference","volume":"22","author":"Reynolds","year":"2004","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113681_bb0470","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1167\/iovs.04-0528","article-title":"Characterization of growth and differentiation in a telomerase-immortalized human corneal epithelial cell line","volume":"46","author":"Robertson","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2025.113681_bb0475","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.exer.2019.02.003","article-title":"A technical protocol for an experimental ex vivo model using arterially perfused porcine eyes","volume":"181","author":"Rousou","year":"2019","journal-title":"Exp. Eye Res."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113681_bb0480","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41576-019-0100-z","article-title":"Induced pluripotent stem cells in disease modelling and drug discovery","volume":"20","author":"Rowe","year":"2019","journal-title":"Nat. Rev. Genet."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113681_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101299","article-title":"Toward a large-batch manufacturing process for silicon-stabilized lipid nanoparticles: A highly customizable RNA delivery platform","volume":"32","author":"Saffie-Siebert","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113681_bb0490","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11427-018-9438-y","article-title":"siRNA therapeutics: a clinical reality","volume":"63","author":"Saw","year":"2020","journal-title":"Sci. China Life Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113681_bb0495","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.gim.2021.10.024","article-title":"Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children","volume":"24","author":"Sas","year":"2022","journal-title":"Genitourin. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113681_bb0500","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113681_bb0505","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nmeth780","article-title":"siRNA design including secondary structure target site prediction","volume":"2","author":"Schramm","year":"2005","journal-title":"Nat. Methods"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113681_bb0510","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: First Approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113681_bb0515","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: first approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113681_bb0520","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.vascn.2010.09.005","article-title":"Effect of biological matrix and sample preparation on qPCR quantitation of siRNA drugs in animal tissues","volume":"63","author":"Seitzer","year":"2011","journal-title":"J. Pharmacol. Toxicol. Methods"},{"issue":"11","key":"10.1016\/j.jconrel.2025.113681_bb0525","first-page":"1612","article-title":"Death but one unintended consequence of gene-therapy trial","volume":"164","author":"Sibbald","year":"2001","journal-title":"Can. Med. Assoc. J."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113681_bb0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-020-1045-7","article-title":"Successful delivery of large-size CRISPR\/Cas9 vectors in hard-to-transfect human cells using small plasmids","volume":"3","author":"S\u00f8ndergaard","year":"2020","journal-title":"Commun. Biol."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113681_bb0535","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41576-019-0150-2","article-title":"RNA sequencing: the teenage years","volume":"20","author":"Stark","year":"2019","journal-title":"Nat. Rev. Genet."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113681_bb0540","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3390\/genes11050511","article-title":"Efficient generation and correction of mutations in human iPS cells utilizing mRNAs of CRISPR Base editors and prime editors","volume":"11","author":"S\u00fcr\u00fcn","year":"2020","journal-title":"Genes"},{"issue":"7","key":"10.1016\/j.jconrel.2025.113681_bb0545","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40265-021-01511-3","article-title":"Givosiran: A review in acute hepatic Porphyria","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113681_bb0550","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.3390\/ijms24032882","article-title":"Cytoprotective effects of human platelet lysate during the Xeno-free culture of human donor corneas","volume":"24","author":"Talpan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113681_bb0555","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41467-023-35886-6","article-title":"Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing","volume":"14","author":"Tao","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.113681_bb0560","author":"The Human Gene Mutation Database"},{"issue":"24","key":"10.1016\/j.jconrel.2025.113681_bb0565","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1101\/gad.13.24.3191","article-title":"Targeted mRNA degradation by double-stranded RNA in vitro","volume":"13","author":"Tuschl","year":"1999","journal-title":"Genes Dev."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113681_bb0570","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/nar\/gkh247","article-title":"Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference","volume":"32","author":"Ui-Tei","year":"2004","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113681_bb0575","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1261\/rna.7272305","article-title":"The contributions of dsRNA structure to Dicer specificity and efficiency","volume":"11","author":"Vermeulen","year":"2005","journal-title":"RNA"},{"key":"10.1016\/j.jconrel.2025.113681_bb0580","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1186\/1471-2105-7-520","article-title":"An accurate and interpretable model for siRNA efficacy prediction","volume":"7","author":"Vert","year":"2006","journal-title":"BMC Bioinf."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113681_bb0585","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/ICO.0000000000000307","article-title":"IC3D classification of corneal dystrophies--edition 2","volume":"34","author":"Weiss","year":"2015","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113681_bb0590","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/10409238.2016.1143913","article-title":"PP2A as a master regulator of the cell cycle","volume":"51","author":"Wlodarchak","year":"2016","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.jconrel.2025.113681_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115073","article-title":"RNAi therapies: expanding applications for extrahepatic diseases and overcoming delivery challenges","volume":"201","author":"Won Lee","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.jconrel.2025.113681_bb0600","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133397","article-title":"Development of a transgenic mouse with R124H human TGFBI mutation associated with granular corneal dystrophy type 2","volume":"10","author":"Yamazoe","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113681_bb0605","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/17512433.2019.1567326","article-title":"Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"12","author":"Yang","year":"2019","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113681_bb0610","first-page":"1","article-title":"Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia","volume":"12","author":"Yun","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113681_bb0615","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jcph.1480","article-title":"Patisiran pharmacokinetics, pharmacodynamics, and exposure-response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113681_bib616","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13506129.2016.1160882","article-title":"Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis","volume":"23","author":"Butler","year":"2016","journal-title":"Amyloid\u202f: the international journal of experimental and clinical investigation\u202f: the official journal of the International Society of Amyloidosis"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113681_bib617","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12896-018-0415-4","article-title":"Two approaches for estimating the lower limit of quantitation (LLOQ) of microRNA levels assayed as exploratory biomarkers by RT-qPCR","volume":"18","author":"Wolfinger","year":"2018","journal-title":"BMC biotechnology"},{"key":"10.1016\/j.jconrel.2025.113681_bib618","unstructured":"ICH guideline S12 on nonclinical biodistribution considerations for gene therapy products - Step 2b - Scientific guideline(2021) Available at: https:\/\/www.ema.europa.eu\/en\/ich-guideline-s12-nonclinical-biodistribution-considerations-gene-therapy-products-step-2b-scientific-guideline [Accessed Jan 22, 2024]."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925003013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925003013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:00:15Z","timestamp":1777870815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925003013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":126,"alternative-id":["S0168365925003013"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113681","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TGFBI R124H mutant allele silencing in granular corneal dystrophy type 2 using topical siRNA delivery","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113681"}}